Fundraising Fox
Exicure
NASDAQ: XCURSkokie, US · Founded 2011 · Delaware corporation · 5 employees on LinkedIn · 5 known investors
Find your way into Exicure
101 people in our graph share verified history with the Exicure team — schools, employers, funds. One of them is your warm intro.
Exicure is a publicly-traded holding company that previously developed nucleic acid therapies and has since divested its historical biotechnology assets; it is now pursuing growth through acquisitions and partnerships, including a recent investment in GPCR Therapeutics USA, which is developing small molecule therapies for blood cancers and multiple myeloma.
Founders & leadership
Exicure was founded in 2011 by Chad A. Mirkin, C. Shad Thaxton, and David A. Giljohann.
Board
Investors · 5
How we know: the S-1 prospectus · funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$33.6M disclosed across 3 of 4 rounds · 2011–2024
- Undisclosed amountequity financingDec 2024
HiTron Systems
Source ↗
▶$14.8MraisedOct 2015 · 16 investors · BiotechnologyRule 506(b)
- Chad A. MirkinDirector
- C. Shad ThaxtonDirector
- David A. GiljohannExecutive Officer, Director
- Helen KimDirector
- Jay VenkatesanDirector
- David R. WaltDirector
- David S. SnyderExecutive Officer
- Amount sold
- $14.8M
- First sale
- Oct 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$13.4MraisedJun 2014 · 35 investors · BiotechnologyRule 506(b)
- Chad A. MirkinExecutive Officer, Director
- C. Shad ThaxtonExecutive Officer, Director
- David WaltDirector
- David A. GiljohannExecutive Officer, Director
- Jay VenkatesanDirector
- Amount sold
- $13.4M
- Minimum investment
- $50K
- First sale
- Jun 2014
- Incorporated
- Limited Liability Company, Delaware, 2011
- Federal exemptions
- 06b
▶$5.4MraisedJan 2012 · 30 investors · BiotechnologyRule 506(b)
- Percy Van Crocker, Jr.Executive Officer
- Chad A. MirkinExecutive Officer, Director
- C. Shad ThaxtonExecutive Officer, Director
- Amount sold
- $5.4M
- Minimum investment
- $15K
- First sale
- Dec 2011
- Incorporated
- Limited Liability Company, Delaware, 2011
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Exicure went on to found or lead other companies.
Frequently asked questions
- What does Exicure do?
- Exicure is a publicly-traded holding company that previously developed nucleic acid therapies and has since divested its historical biotechnology assets; it is now pursuing growth through acquisitions and partnerships, including a recent investment in GPCR Therapeutics USA, which is developing small molecule therapies for blood cancers and multiple myeloma.
- Who founded Exicure?
- Exicure was founded by Chad A. Mirkin, C. Shad Thaxton, David A. Giljohann in 2011.
- Who are Exicure's investors?
- Exicure's investors include AbbVie, Innovation Endeavors, Purple Arch Ventures, RockPort Capital Partners.
- How much funding has Exicure raised?
- Exicure has disclosed $33.6M raised across 3 of its 4 known rounds.
- Where is Exicure headquartered?
- Exicure is headquartered in Skokie, US.